Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis

Tsai, Yieh-Loong; Hung, Cheng‐Chieh; Tsai, Tsen‐Fang

doi:10.3390/pharmaceutics15051351

Cited by 13 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent network meta-analysis assessing the efficacy and safety of various biologic antibodies and other drugs under investigation for HS provided some notable findings. Notably, the efficacy of bimekizumab, as assessed by the HiSCR in weeks 12-16, was statistically non-inferior to that of adalimumab [68].…”

Section: Discussionmentioning

confidence: 92%

IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa

Malvaso,

Calabrese,

Chiricozzi

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a significant negative impact on the quality of life of patients. To date, the therapeutic landscape for the management of the disease has been extremely limited, resulting in a profound unmet need. Indeed, adalimumab, an anti-tumor necrosis factor (TNF)-α monoclonal antibody, is the only approved biologic agent for HS, obtaining a therapeutic response in only 50% of HS patients. Numerous clinical trials are currently ongoing to test novel therapeutic targets in HS. The IL-17-mediated cascade is the target of several biologic agents that have shown efficacy and safety in treating moderate-to-severe HS. Both bimekizumab and secukinumab, targeting IL-17 in different manners, have successfully completed phase III trials with promising results; the latter has recently been approved by EMA for the treatment of HS. The aim of this review is to summarize the current state of knowledge concerning the relevant role of IL-17 in HS pathogenesis, highlighting the key clinical evidence of anti-IL-17 agents in the treatment of this disease.

show abstract

Section: Discussionmentioning

confidence: 92%

IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa

Malvaso,

Calabrese,

Chiricozzi

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…На сегодняшний день известно множество схем лечения суппуративного гидраденита с применением системной и наружной терапии, но их доказательная база невелика в связи с отсутствием достаточного количества клинических исследований в этой области [21,22]. В наружной терапии применяются антисептические растворы, местные антибактериальные препараты, ихтиол [23]. Системная терапия суппуративного гидраденита может включать антибиотики, глюкокортикоиды, ретиноиды, а в самых тяжелых случаях -генно-инженерные биологические препараты [23,24].…”

Section: обоснованиеunclassified

“…В наружной терапии применяются антисептические растворы, местные антибактериальные препараты, ихтиол [23]. Системная терапия суппуративного гидраденита может включать антибиотики, глюкокортикоиды, ретиноиды, а в самых тяжелых случаях -генно-инженерные биологические препараты [23,24]. Последние, главным образом инфликсимаб и адалимумаб, показали положительный эффект в сериях случаев у взрослых [25], но опыт применения биологических препаратов в педиатрической практике крайне мал, а в практике отечественных дерматовенерологов отсутствует [22].…”

Section: обоснованиеunclassified

“…Последние, главным образом инфликсимаб и адалимумаб, показали положительный эффект в сериях случаев у взрослых [25], но опыт применения биологических препаратов в педиатрической практике крайне мал, а в практике отечественных дерматовенерологов отсутствует [22]. При этом тактика терапии определяется степенью тяжести суппуративного гидраденита и наличием сопутствующих заболеваний [23]. Изменения кожного покрова, обусловленные синдромом Рэппа -Ходжкина, а именно нарушение барьерной функции кожи и фолликулярный гиперкератоз, отягощают течение суппуративного гидраденита [24].…”

Section: обоснованиеunclassified

See 1 more Smart Citation

Adalimumab Experience in the Management of Hidradenitis Suppurativa Burdened with Rapp-Hodgkin Syndrome

Murashkin,

Materikin,

Epishev

et al. 2023

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

Background. Rapp-Hodgkin syndrome is a rare genetic disease from the ectodermal dysplasia group. It manifests with damage of ectodermal structures — layer of embrional tissue that provides the development of many organs and tissues in the body, such as: skin, sweat glands, hair, teeth, and nails. Disease symptoms may range from mild to severe and include dental abnormalities, fragile, thin or no hair, abnormal nails, hypohidrosis (due to the reduced number of sweat glands), cleft lips and palate. Hidradenitis suppurativa is a chronic inflammatory disease that predominantly affects apocrine glands areas. This nosology is characterized by painful nodes, abscesses, and fistulas, prone to relapses and leading to scarring.Clinical case description. The authors present a clinical case demonstrating the combination of Rapp-Hodgkin syndrome and severe hidradenitis suppurativa in 17-year-old male patient.Conclusion. The heterogeneous clinical findings of hidradenitis suppurativa and history of rare genetic disease result in patients' admissions to various medical specialists. Thus, it leads to delayed verification of the diagnosis and incorrect treatment methods. As a result, patients have persistent cosmetic skin defects, possible complications of irrational treatment, and decreased quality of life by the time of diagnosis.

show abstract

“…However, a substantial proportion of individuals fail to achieve treatment objectives and face frequent relapses. 20 Consequently, there remains a pressing need to explore novel targets for improved therapeutic outcomes in HS.…”

Section: Introductionmentioning

confidence: 99%

Discovering KYNU as a feature gene in hidradenitis suppurativa

Liang,

Yu,

Tang

et al. 2023

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Background Hidradenitis suppurativa (HS) is a chronic auto-inflammatory skin condition characterized by nodules, abscesses, and fistulae in skin folds. The underlying pathogenesis of HS remains unclear, and effective therapeutic drugs are limited. Methods We acquired mRNA expression profiles from the Gene Expression Omnibus (GEO) database and conducted differential expression analysis between control and HS samples using R software. Four machine learning algorithms (SVM, RF, ANN, and lasso) and WCGNA were utilized to identify feature genes. GO, KEGG, Metascape, and GSVA were utilized for the enrichment analysis. CIBERSORT and ssGSEA were employed to analyze immune infiltration. Results A total of 29 DEGs were identified, with the majority showing up-regulation in HS. Enrichment analysis revealed their involvement in immune responses and cytokine activities. KEGG analysis highlighted pathways such as IL-17 signaling, rheumatoid arthritis, and TNF signaling in HS. Immune infiltration analysis revealed the predominant presence of neutrophils, monocytes, and CD8 T cells. Machine learning algorithms and WCGNA identified KYNU as a feature gene associated with HS. We have also identified 59 potential drugs for HS based on the DEGs. Additionally, ceRNA network analysis identified the MUC19_hsa-miR-382-5p_KYNU pathway as a potential regulatory pathway. Conclusions KYNU emerged as a feature gene associated with HS, and the ceRNA network analysis identified the MUC19_hsa-miR-382-5p_KYNU pathway as a potential regulator.

show abstract

Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis

Cited by 13 publications

References 42 publications

IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa

IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa

Adalimumab Experience in the Management of Hidradenitis Suppurativa Burdened with Rapp-Hodgkin Syndrome

Discovering KYNU as a feature gene in hidradenitis suppurativa

Contact Info

Product

Resources

About